- Language: English
- 3562 Pages
- Published: August 2014
- Region: Global
Atherosclerosis Partnering 2010-2015
- ID: 2074742
- March 2015
- Region: Global
- 100 Pages
The Atherosclerosis Partnering 2010-2015 report provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in atherosclerosis partnering deals
Top atherosclerosis deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
The Atherosclerosis Partnering 2010-2015 provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of atherosclerosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors atherosclerosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 35 links to online copies of actual atherosclerosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of atherosclerosis partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.
Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.
Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.
Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of atherosclerosis technologies and products.
Atherosclerosis Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to atherosclerosis trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in atherosclerosis dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 35 atherosclerosis deals and contract documents where available
The leading atherosclerosis deals by value since 2010
In Atherosclerosis Partnering 2010-2015, the available deals are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
* Please note this is an on-demand product, please allow 3-5 working days for delivery. SHOW LESS READ MORE >
Chapter 1 – Introduction
Chapter 2 – Trends in atherosclerosis partnering
2.2. Atherosclerosis partnering over the years
2.3. Atherosclerosis partnering by deal type
2.4. Atherosclerosis partnering industry sector
2.5. Atherosclerosis partnering by stage of development
2.6. Atherosclerosis partnering by technology type
Chapter 3 – Average deal terms for atherosclerosis
3.2 Average deal terms for atherosclerosis
3.3 Atherosclerosis headline values with median calculation
3.4 Atherosclerosis upfront values with median calculation
3.5 Atherosclerosis milestone values with median calculation
3.6 Atherosclerosis royalty rates with median calculation
Chapter 4 – Active atherosclerosis dealmakers
4.2 Most active atherosclerosis dealmakers
4.3. Top atherosclerosis deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity
Chapter 5 – Atherosclerosis dealmaking directory
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type
Chapter 6 – Partnering resource center
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
Appendix 1 – Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Order Form – Reports
Order Form – Subscription Access Products
Table of figures
Figure 1: Atherosclerosis partnering since 2010
Figure 2: Atherosclerosis dealmaking activity– 2010 to 2015
Figure 3: Atherosclerosis partnering by deal type since 2010
Figure 4: Atherosclerosis partnering by industry sector since 2010
Figure 5: Atherosclerosis partnering by stage of development since 2010
Figure 6: Atherosclerosis partnering by technology type since 2010
Figure 7: Atherosclerosis deals with a headline value
Figure 8: Atherosclerosis deals with upfront payment values
Figure 9: Atherosclerosis deals with milestone payments
Figure 10: Atherosclerosis deals with royalty rates, %
Figure 11: Top atherosclerosis deals by value since 2010
Figure 12: Big pharma – top 50 – atherosclerosis deals 2010 to 2015
Figure 13: Big pharma atherosclerosis deal frequency – 2010 to 2015
Figure 14: Big biotech – top 50 – atherosclerosis deals 2010 to 2015
Figure 15: Big biotech atherosclerosis deal frequency – 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions